ArticleBMC oral health2026
TCIRG1
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTongue squamous cell carcinoma (TSCC) is associated with an unfavorable prognosis, and the involvement of systemic inflammation and tumor-associated neutrophils (TANs) remains inadequately elucidated. This study was designed to assess the prognostic significance of inflammatory biomarkers and to delineate functionally distinct TAN subsets in TSCC.
methodsThis retrospective investigation enrolled 851 patients with TSCC, stratified into discovery (n = 596) and validation (n = 255) cohorts. Pre-treatment hematological parameters were utilized to compute systemic inflammatory indices, including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). Neutrophil infiltration was quantitatively evaluated through hematoxylin and eosin (H&E) staining and multiplex immunohistochemistry (mIHC) in a representative subset of 120 cases. Proteomic profiling facilitated the identification of neutrophil-associated genes, whose prognostic relevance was subsequently corroborated through analysis of The Cancer Genome Atlas (TCGA) dataset and mIHC validation.
resultElevated NLR and MLR were associated with diminished overall and disease-free survival, with NLR demonstrating superior predictive capability. Increased intratumoral neutrophil density was significantly correlated with unfavorable clinical outcomes. Proteomic profiling identified T cell immunoregulatory protein 1 (TCIRG1) as a pivotal gene associated with neutrophil activity. mIHC analysis demonstrated that the density of TCIRG1
conclusionNLR is robust prognostic biomarker in TSCC. The TCIRG1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.